Form 8-K - Current report:
SEC Accession No. 0001558370-24-008555
Filing Date
2024-05-22
Accepted
2024-05-22 08:30:16
Documents
20
Period of Report
2024-05-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20240522x8k.htm   iXBRL 8-K 43778
2 EX-99.1 nrbo-20240522xex99d1.htm EX-99.1 38625
3 GRAPHIC nrbo-20240522x8k001.jpg GRAPHIC 12152
4 GRAPHIC nrbo-20240522xex99d1001.jpg GRAPHIC 12969
5 GRAPHIC nrbo-20240522xex99d1002.jpg GRAPHIC 17292
6 GRAPHIC nrbo-20240522xex99d1003.jpg GRAPHIC 16246
7 GRAPHIC nrbo-20240522xex99d1004.jpg GRAPHIC 20709
8 GRAPHIC nrbo-20240522xex99d1005.jpg GRAPHIC 55795
  Complete submission text file 0001558370-24-008555.txt   412632

Data Files

Seq Description Document Type Size
9 EX-101.SCH nrbo-20240522.xsd EX-101.SCH 3147
10 EX-101.LAB nrbo-20240522_lab.xml EX-101.LAB 15266
11 EX-101.PRE nrbo-20240522_pre.xml EX-101.PRE 9672
23 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20240522x8k_htm.xml XML 4690
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 24971687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)